CAH
44
7
AEE
51
3
WM
53
2
XEL
48
11
CF
47
5
DE
49
3
XYL
29
4
DNB
72
4
STX
34
2
DG
14
6
GME
61
2
ADT
12
2
BIIB
36
8
V
70
14
SWK
53
4
JWN
72
9
DVA
62
5
PVH
58
5
RL
73
5
CINF
24
-8
CAH
44
7
AEE
51
3
WM
53
2
XEL
48
11
CF
47
5
DE
49
3
XYL
29
4
DNB
72
4
STX
34
2
DG
14
6
GME
61
2
ADT
12
2
BIIB
36
8
V
70
14
SWK
53
4
JWN
72
9
DVA
62
5
PVH
58
5
RL
73
5
CINF
24
-8
Financhill
Back

AstraZeneca PLC 10K Form

Sell
41

AZN
AstraZeneca PLC

Last Price:
$65.36
Seasonality Move:
0.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AZN News And Ratings

See the #1 stock for the next 7 days that we like better than AZN

AZN Financial Statistics

Sales & Book Value

Annual Sales: $45.8B
Cash Flow: $2B
Price / Cash Flow: 30.23
Annual Sales: $13.13
Price / Book: 4.98

Profitability

EPS (TTM): 2.08500
Net Income (TTM): $6.5B
Gross Margin: $37.5B
Return on Equity: 16.72%
Return on Assets: 6.38%

AstraZeneca PLC Earnings Forecast

Key AstraZeneca PLC Financial Ratios

  • The Gross Profit Margin over the past 26 years for AZN is 81.95%.
  • The Selling, General & Administrative Expenses for AZN have been equal to 39.78% of Gross Profit Margin.
  • The Research & Development expenses have been 23.87% of Revenue.
  • The Interest Expense is 26.68% of Operating Income.
  • The Net Earning history of AZN is 13.00% of Total Revenues.
  • Per Share Earnings over the last 34 years have been positive in 19 years.

AstraZeneca PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AZN
CUSIP: 046353
Website: astrazeneca.com

Debt

Debt-to-Equity Ratio: 0.74
Current Ratio: 0.93
Quick Ratio: 0.71

Price-to-Earnings

Trailing P/E Ratio: 34.31
Forward P/E Ratio: 13.69

AZN Technical Analysis vs Fundamental Analysis

Sell
41
AstraZeneca PLC (AZN) is a Sell

Is AstraZeneca PLC a Buy or a Sell?

  • AstraZeneca PLC stock is rated a Sell
    The current AstraZeneca PLC [AZN] share price is $65.36. The Score for AZN is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.